Lyra Therapeutics Net Worth
Lyra Therapeutics Net Worth Breakdown | LYRA |
Lyra Therapeutics Net Worth Analysis
Lyra Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Lyra Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Lyra Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Lyra Therapeutics' net worth analysis. One common approach is to calculate Lyra Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Lyra Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Lyra Therapeutics' net worth. This approach calculates the present value of Lyra Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Lyra Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Lyra Therapeutics' net worth. This involves comparing Lyra Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Lyra Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Lyra Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Lyra Therapeutics' net worth research are outlined below:
| Lyra Therapeutics generated a negative expected return over the last 90 days | |
| Lyra Therapeutics has high historical volatility and very poor performance | |
| Lyra Therapeutics has some characteristics of a very speculative penny stock | |
| Lyra Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1.56 M. Net Loss for the year was (62.68 M) with loss before overhead, payroll, taxes, and interest of (34.23 M). | |
| Lyra Therapeutics currently holds about 120.67 M in cash with (63.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 59.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Lyra Therapeutics Inc Q3 2024 Earnings Net Loss of 11.9M, Misses EPS and Revenue Estimates |
Lyra Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Lyra Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lyra Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Lyra Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Lyra Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lyra Therapeutics backward and forwards among themselves. Lyra Therapeutics' institutional investor refers to the entity that pools money to purchase Lyra Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Everhart Financial Group, Inc. | 2024-09-30 | 252.7 K | Boothbay Fund Management, Llc | 2024-09-30 | 232.7 K | Northern Trust Corp | 2024-09-30 | 183.3 K | Exoduspoint Capital Management, Lp | 2024-09-30 | 159.2 K | New York State Common Retirement Fund | 2024-09-30 | 154.8 K | Simplex Trading, Llc | 2024-06-30 | 129.1 K | Charles Schwab Investment Management Inc | 2024-09-30 | 111.6 K | Bank Of America Corp | 2024-06-30 | 86.5 K | Bank Of New York Mellon Corp | 2024-06-30 | 77.4 K | Perceptive Advisors Llc | 2024-09-30 | 12.8 M | Citadel Advisors Llc | 2024-09-30 | 4.8 M |
Follow Lyra Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.37 M.Market Cap |
|
Project Lyra Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.55) | (0.57) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.70) | (0.74) |
When accessing Lyra Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Lyra Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Lyra Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Lyra Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Lyra Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Lyra Therapeutics' management manipulating its earnings.
Evaluate Lyra Therapeutics' management efficiency
Lyra Therapeutics has return on total asset (ROA) of (0.4229) % which means that it has lost $0.4229 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8618) %, meaning that it created substantial loss on money invested by shareholders. Lyra Therapeutics' management efficiency ratios could be used to measure how well Lyra Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.46. In addition to that, Return On Capital Employed is expected to decline to -0.57. At present, Lyra Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 39.7 M, whereas Total Assets are forecasted to decline to about 78.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.80 | 1.89 | |
| Tangible Book Value Per Share | 1.80 | 1.89 | |
| Enterprise Value Over EBITDA | (4.07) | (4.27) | |
| Price Book Value Ratio | 2.92 | 2.77 | |
| Enterprise Value Multiple | (4.07) | (4.27) | |
| Price Fair Value | 2.92 | 2.77 | |
| Enterprise Value | 265.5 M | 278.8 M |
The strategic initiatives led by Lyra Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 153.7687 | Revenue 1.5 M | Quarterly Revenue Growth (0.64) | Revenue Per Share 0.023 | Return On Equity (1.86) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lyra Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lyra Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lyra Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Lyra Therapeutics time-series forecasting models is one of many Lyra Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lyra Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Lyra Therapeutics Earnings per Share Projection vs Actual
Lyra Therapeutics Corporate Management
| Dr Roberts | CoFounder | Profile | |
| Corinne Noyes | Senior Development | Profile | |
| Donald MBA | Advisor | Profile | |
| Gloria Cosgrove | Senior Quality | Profile | |
| Ellen Cavaleri | Senior Communications | Profile | |
| Richard MD | Chief Officer | Profile | |
| Ronan JD | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyra Therapeutics. If investors know Lyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.49) | Revenue Per Share 0.023 | Quarterly Revenue Growth (0.64) | Return On Assets (0.42) | Return On Equity (1.86) |
The market value of Lyra Therapeutics is measured differently than its book value, which is the value of Lyra that is recorded on the company's balance sheet. Investors also form their own opinion of Lyra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lyra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyra Therapeutics' market value can be influenced by many factors that don't directly affect Lyra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.